71 results about "Nociception" patented technology

A system and method identifies different components of the pain experience (nociceptive (tissue damage), neuropathic (nerve damage) and psychological) and their relative contributions by the use of magnetic resonance spectroscopy (MRS) to measure absolute and relative concentrations of metabolites in specific brain regions in the central nervous system or brain. The system and method can be used as a diagnostic tool for the assessment of the relative contribution of different aspects of the pain experience as well as monitoring of response to interventions directed at modifying these components.

The invention relates to the determination of the anesthetic state of a patient. In order to achieve a mechanism that enables establishment and maintenance of balanced anesthesia, values are established for a set of diagnostic indices. The set includes at least two diagnostic indices of which a first diagnostic index is indicative of the level of hypnosis and a second diagnostic index of the level of nociception in the patient. The combination of the at least two index values obtained is employed for indicating the anesthetic state of the patient. The combination of the at least two index values may further be employed to control the administration of drugs to the patient.

Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a NaV1.7 channel protein or a complete humanization of an endogenous NaV1.7 gene. Methods for using isolated DRG cultures from genetically modified non-human animals are also provided, wherein the isolated DRG express a human or chimeric NaV1.7 protein on the surface, in particular measuring primary nociceptive activation through the release of calcitonin gene-related peptide (CGRP) in isolated DRG in vitro, and wherein the isolated DRG cultures are capable of generating action potentials and communicating through an excitable signal via the expressed human or chimeric NaV1.7 protein the cell surface. In vivo and in vitro methods for characterizing NaV1.7-specific antagonists and evaluation of corresponding therapeutic potential for NaV1.7-mediated disease are also provided.

A compound of the formula (I), (II), (III) or (IV) whereinZ, A, B, C, R, R1, R2, Q, and n are as described herein.

Disclosed are compounds of the formula (I)wherein A, R1, R2, R3, R4 and X1 are as disclosed herein. The compounds have affinity for the ORL1 receptor and are useful in the treatment of chronic and acute pain.

The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and / or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and / or nociception in an individual.

A compound of the having the general formula (I) or general formula (II): wherein Z, A, B, C, R1, R2, Q, W, and n are as described herein.

The invention provides an application of a peptide containing an amino acid sequence YEKLLDTEI or functional variants thereof or pharmaceutical composition containing the peptide in preparation of drugs for preventing, relieving or treating pain, particularly nociceptive pain as well as a method for preventing, relieving or treating the pain.

The present invention relates to nociceptin analogues and uses thereof to modulate biological functions. In one aspect, the invention provides modified triazo-spiro compounds that include at least one specialized chemical group that is bound to the compounds. The invention has a wide range of applications including providing a new class of therapeutically useful aquatics.

The invention relates to the determination of the clinical state of a subject. In order to bring about an uncomplicated method for monitoring the clinical state of a subject and for accomplishing a diagnostic scale, such as a nociception scale, on which a certain reading corresponds to the same level for all patients, a normalization transform is applied to a measurement signal containing physiological data obtained from a patient, whereby a normalized measurement signal having a predetermined value range is obtained. The normalization transform is dependent on predetermined history data, such as previous signal data of said measurement signal. A diagnostic index dependent on the normalized measurement signal is then formed, the diagnostic index serving as a measure of the clinical state of the patient. The diagnostic index may be formed based on one or more normalized measurement signals.

The present invention relates to an antipruritic agent comprising a nociceptine antagonist as an active ingredient. The nociceptine antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scratching behavior suppressing effect, that is, antiitching effect and antipruritic effect.

Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of neuroglia-derived BDNF expression or activity. Also described herein are commercial packages and uses based on such modulation. Related methods for identifying or characterizing compounds for the treatment of pain and the reduction of nociception are also described.